Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | NOS2 | P35228 | 3/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HLCS | P50747 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10437624 | 0.98 | CYP1A2 (0.39) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL9189340 | 0.98 | CYP1A2 (0.39) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL5145497 | 0.98 | CYP1A2 (0.39) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL11313115 | 0.98 | CYP1A2 (0.39) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL6933305 | 0.98 | CYP1A2 (0.39) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL5145224 | 0.98 | CYP1A2 (0.39) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL3265923 | 0.86 | NOS1 (0.31) | NOS1NOS2NOS3 | |
| SCHEMBL2449791 | 0.82 | ALDH1A1 (0.47) | CYP1A2ALDH1A1CYP19A1PPARG | |
| SCHEMBL8359629 | 0.82 | ALDH1A1 (0.47) | CYP1A2ALDH1A1CYP19A1PPARG | |
| SCHEMBL10937715 | 0.81 | CYP1A2 (0.41) | CYP1A2ALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4578474-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-03-25 | — | — | US | claimed |
| EP-0042639-B1 | AZIDO, IMIDO, AMIDO AND AMINO DERIVATIVES OF MERCAPTOACYL PROLINES AND PIPECOLIC ACIDS HAVING HYPOTENSIVE ACTIVITY | E.R. Squibb & Sons, Inc. (US) | 1984-08-22 | — | — | EP | claimed |
| EP-0042639-A2 | Azido, imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids having hypotensive activity | E.R. Squibb & Sons, Inc. (US) | 1981-12-30 | — | — | EP | claimed |
| US-20050272649-A1 | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure | STRYKER CORPORATION | 2005-12-08 | — | — | US | disclosed |
| EP-1578360-A2 | CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE | Curis, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004019876-A2 | CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE | CURIS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-4578474-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-03-25 | — | — | US | disclosed |
| US-4497953-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-05 | — | — | US | disclosed |
| EP-0042639-B1 | AZIDO, IMIDO, AMIDO AND AMINO DERIVATIVES OF MERCAPTOACYL PROLINES AND PIPECOLIC ACIDS HAVING HYPOTENSIVE ACTIVITY | E.R. Squibb & Sons, Inc. (US) | 1984-08-22 | — | — | EP | disclosed |
| US-4390695-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1983-06-28 | — | — | US | disclosed |
| US-4310461-A | HYPTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-12 | — | — | US | disclosed |
| EP-0042639-A2 | Azido, imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids having hypotensive activity | E.R. Squibb & Sons, Inc. (US) | 1981-12-30 | — | — | EP | disclosed |
| EP-0042639-A2 | Azido, imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids having hypotensive activity | E.R. Squibb & Sons, Inc. (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4124512-A | Oil recovery by waterflooding employing succinimido aryl sulfonate surfactants | MOBIL OIL CORPORATION (US) | 1978-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272649-A1 | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure | BMPR2, BMP2, BMP1 | CYP1A2 1382/4885NOS1 1435/4885NOS2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.